SEC Comment Letter for SciSparc Ltd. (SPRC) (CIK 0001611746) (SPRC) — Jul 13, 2018
SciSparc Ltd. (SPRC) (CIK 0001611746)
Date: July 13, 2018 · CIK: 0001611746 · Accession: 0000000000-18-021630
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-225745
Letter
July 13, 2018 Ascher Shmulewitz Chief Executive Officer Therapix Biosciences Ltd. 4 Ariel Sharon Street HaShahar Tower, 16th Floor Givatayim 5320047, Israel Re:Therapix Biosciences Ltd. Registration Statement on Form F-3 Response dated July 10, 2018 File No. 333-225745 Dear Dr. Shmulewitz: We have reviewed your response dated July 10, 2018 and have the following comment. In our comment, we may ask you to provide us with information so we may better understand your disclosure. Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your registration statement and the information you provide in response to this comment, we may have additional comments. Unless we note otherwise, our references to prior comments are to comments in our July 9, 2018 letter. Registration Statement on Form F-3 filed June 20, 2018 Description of Securities, page 8 1.We note your response to our comment. Please revise your registration statement to disclose the existence of the arbitration provision and, if true, to state that the arbitration provision is not mandatory and does not prevent ADS holders or ordinary shareholders from pursuing claims under the United States federal securities laws. To the extent this is not correct, please explain in your response.
FirstName LastNameAscher Shmulewitz Comapany NameTherapix Biosciences Ltd. July 13, 2018 Page 2 FirstName LastName Ascher Shmulewitz Therapix Biosciences Ltd. July 13, 2018 Page 2 Please contact Irene Paik at 202-551-6553 or Erin Jaskot at 202-551-3442 with any questions. Division of Corporation Finance Office of Healthcare & Insurance cc: Jeffrey Schultz
Show Raw Text
July 13, 2018
Ascher Shmulewitz
Chief Executive Officer
Therapix Biosciences Ltd.
4 Ariel Sharon Street
HaShahar Tower, 16th Floor
Givatayim 5320047, Israel
Re:Therapix Biosciences Ltd.
Registration Statement on Form F-3
Response dated July 10, 2018
File No. 333-225745
Dear Dr. Shmulewitz:
We have reviewed your response dated July 10, 2018 and have the following comment.
In our comment, we may ask you to provide us with information so we may better understand
your disclosure.
Please respond to this letter by amending your registration statement and providing the
requested information. If you do not believe our comment applies to your facts
and circumstances or do not believe an amendment is appropriate, please tell us why in
your response.
After reviewing any amendment to your registration statement and the information you
provide in response to this comment, we may have additional comments. Unless we note
otherwise, our references to prior comments are to comments in our July 9, 2018 letter.
Registration Statement on Form F-3 filed June 20, 2018
Description of Securities, page 8
1.We note your response to our comment. Please revise your registration statement to
disclose the existence of the arbitration provision and, if true, to state that the arbitration
provision is not mandatory and does not prevent ADS holders or ordinary shareholders
from pursuing claims under the United States federal securities laws. To the extent this is
not correct, please explain in your response.
FirstName LastNameAscher Shmulewitz
Comapany NameTherapix Biosciences Ltd.
July 13, 2018 Page 2
FirstName LastName
Ascher Shmulewitz
Therapix Biosciences Ltd.
July 13, 2018
Page 2
Please contact Irene Paik at 202-551-6553 or Erin Jaskot at 202-551-3442 with
any questions.
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Jeffrey Schultz